Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania. (2019)

First Author: Anywaine Z
Attributed to:  Pathogen Genomics, Phenotype and Immunity (PGPI) & Basic Sciences Programme funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/infdis/jiz070

PubMed Identifier: 30796818

Publication URI: http://europepmc.org/abstract/MED/30796818

Type: Journal Article/Review

Volume: 220

Parent Publication: The Journal of infectious diseases

Issue: 1

ISSN: 0022-1899